These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32701725)

  • 21. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection.
    Ploussard G; de la Taille A
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):1013-1020. PubMed ID: 30016891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
    Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
    World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
    Luo Y; Gou X; Huang P; Mou C
    Asian J Androl; 2014; 16(3):487-92. PubMed ID: 24713827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
    Bernardeau S; Charles T; Fromont-Hankard G; Irani J
    Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
    Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
    Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.
    Loeb S; Lilja H; Vickers A
    Curr Opin Urol; 2016 Sep; 26(5):459-65. PubMed ID: 27262138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.
    Fenstermaker M; Mendhiratta N; Bjurlin MA; Meng X; Rosenkrantz AB; Huang R; Deng FM; Zhou M; Huang WC; Lepor H; Taneja SS
    Urology; 2017 Jan; 99():174-179. PubMed ID: 27562202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Molecular Markers for Prostate Cancer Diagnosis.
    Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
    Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.
    Hendriks RJ; Dijkstra S; Jannink SA; Steffens MG; van Oort IM; Mulders PF; Schalken JA
    Clin Chem Lab Med; 2016 Mar; 54(3):483-92. PubMed ID: 26630694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Nilsson J; Skog J; Nordstrand A; Baranov V; Mincheva-Nilsson L; Breakefield XO; Widmark A
    Br J Cancer; 2009 May; 100(10):1603-7. PubMed ID: 19401683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
    Minnee P; Hessels D; Schalken JA; Van Criekinge W
    BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary RNA-based biomarkers for prostate cancer detection.
    Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
    Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme.
    Rubio-Briones J; Casanova J; Martínez F; Domínguez-Escrig JL; Fernández-Serra A; Dumont R; Ramírez-Backhaus M; Gómez-Ferrer A; Collado A; Rubio L; Molina A; Vanaclocha M; Sala D; Lopez-Guerrero JA
    Actas Urol Esp; 2017 Jun; 41(5):300-308. PubMed ID: 28342633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.